Management

Adam Sommerfeld

Adam Sommerfeld

Managing partner

MSc & BSc University College London

Previously CEO of DRS-Commodities

Member of the Institute of Directors: British Venture Capital Association, Worshipful Company of International Bankers

Interests: Rugby, Mixed Martial Arts, Sports Tech

RECENT MANDATES:

British Premiership Rugby team seeking an acquisition partner.

English Premiership Football team seeking a majority stakeholder.

US Sports Entertainment complex seeking debt facility.

European Basketball league seeking growth finance.

Genomics based personalized cancer treatment company.

US Pharma developing FDA breakthrough drug for suicidal depression & PTSD.

Privately held DNA testing company, helping to improve cellular health.

US based MedTech developing treatments for venous reflux disease.

Lauren standridge

Senior associate

MSc Stanford Business School

Previously Associate at DRS-Commodities

Member of the Worshipful Company of International Bankers

Interests: Hockey, Antique restoration

RECENT MANDATES:

French Ligue A Football team seeking stadium finance.

European eSports team entering the franchised leagues.

British Motor racing team raising corporate equity.

US Rugby enterprise launching a new international 7s competition.

Personalized AI-powered health information company focused on chronic illness.

US Therapeutics company targeting human obesity.

US dietary supplement company focused on Chronic Kidney disease.

Guy newman allen

Senior associate

MSc INSEAD

Previously Associate Partner at DRS-Commodities

Member of the British Venture Capital Association

Interests: Creative writing, Ultra marathons

RECENT MANDATES:

Global Functional Fitness corporation seeking Olympic recognition.

European events company launching a Global Swimming competition.

Multi-year British Stadium sponsorship deal.

Indian Premier League convertible debt opportunity.

US Biopharma company focused on autoinflammatory orphan diseases.

US MedTech producing Extra Corporeal Membrane Oxygenation technology.

US Pharma developing patented new class of prn medications for acute anxiety.